company background image
CU6 logo

Clarity Pharmaceuticals ASX:CU6 Stock Report

Last Price

AU$5.22

Market Cap

AU$1.6b

7D

0.6%

1Y

560.8%

Updated

15 Jun, 2024

Data

Company Financials +

Clarity Pharmaceuticals Ltd

ASX:CU6 Stock Report

Market Cap: AU$1.6b

CU6 Stock Overview

A clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults.

CU6 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Clarity Pharmaceuticals Ltd Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Clarity Pharmaceuticals
Historical stock prices
Current Share PriceAU$5.22
52 Week HighAU$5.67
52 Week LowAU$0.68
Beta1.55
1 Month Change32.82%
3 Month Change96.98%
1 Year Change560.76%
3 Year Changen/a
5 Year Changen/a
Change since IPO248.00%

Recent News & Updates

Recent updates

Companies Like Clarity Pharmaceuticals (ASX:CU6) Are In A Position To Invest In Growth

Jan 03
Companies Like Clarity Pharmaceuticals (ASX:CU6) Are In A Position To Invest In Growth

We're Interested To See How Clarity Pharmaceuticals (ASX:CU6) Uses Its Cash Hoard To Grow

May 29
We're Interested To See How Clarity Pharmaceuticals (ASX:CU6) Uses Its Cash Hoard To Grow

Companies Like Clarity Pharmaceuticals (ASX:CU6) Are In A Position To Invest In Growth

Aug 24
Companies Like Clarity Pharmaceuticals (ASX:CU6) Are In A Position To Invest In Growth

Here's Why We're Not Too Worried About Clarity Pharmaceuticals' (ASX:CU6) Cash Burn Situation

Jan 13
Here's Why We're Not Too Worried About Clarity Pharmaceuticals' (ASX:CU6) Cash Burn Situation

Shareholder Returns

CU6AU PharmaceuticalsAU Market
7D0.6%1.5%-1.7%
1Y560.8%62.7%7.0%

Return vs Industry: CU6 exceeded the Australian Pharmaceuticals industry which returned 62.7% over the past year.

Return vs Market: CU6 exceeded the Australian Market which returned 7% over the past year.

Price Volatility

Is CU6's price volatile compared to industry and market?
CU6 volatility
CU6 Average Weekly Movement8.8%
Pharmaceuticals Industry Average Movement9.7%
Market Average Movement8.7%
10% most volatile stocks in AU Market16.3%
10% least volatile stocks in AU Market3.2%

Stable Share Price: CU6's share price has been volatile over the past 3 months.

Volatility Over Time: CU6's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
201041Colin Bigginwww.claritypharmaceuticals.com

Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product includes SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2. The company is also developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; and SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen.

Clarity Pharmaceuticals Ltd Fundamentals Summary

How do Clarity Pharmaceuticals's earnings and revenue compare to its market cap?
CU6 fundamental statistics
Market capAU$1.63b
Earnings (TTM)-AU$30.56m
Revenue (TTM)AU$9.49m

171.4x

P/S Ratio

-53.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CU6 income statement (TTM)
RevenueAU$9.49m
Cost of RevenueAU$0
Gross ProfitAU$9.49m
Other ExpensesAU$40.05m
Earnings-AU$30.56m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.098
Gross Margin100.00%
Net Profit Margin-322.18%
Debt/Equity Ratio0%

How did CU6 perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.